| Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials K Clément, E van den Akker, J Argente, A Bahm, WK Chung, H Connors, ... The lancet Diabetes & endocrinology 8 (12), 960-970, 2020 | 302 | 2020 |
| Axon diodes for the reconstruction of oriented neuronal networks in microfluidic chambers JM Peyrin, B Deleglise, L Saias, M Vignes, P Gougis, S Magnifico, ... Lab on a Chip 11 (21), 3663-3673, 2011 | 298 | 2011 |
| Hypogonadism as a reversible cause of torsades de pointes in men JE Salem, X Waintraub, C Courtillot, CM Shaffer, E Gandjbakhch, ... Circulation 138 (1), 110-113, 2018 | 70 | 2018 |
| Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis JE Salem, M Bretagne, B Abbar, S Leonard-Louis, S Ederhy, A Redheuil, ... Cancer Discovery 13 (5), 1100-1115, 2023 | 58 | 2023 |
| Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance A Geraud, P Gougis, A Vozy, C Anquetil, Y Allenbach, E Romano, ... Annual review of pharmacology and toxicology 61, 85-112, 2021 | 58 | 2021 |
| Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study JE Salem, LS Nguyen, JJ Moslehi, S Ederhy, B Lebrun-Vignes, ... European heart journal 42 (38), 3915-3928, 2021 | 56 | 2021 |
| Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma P Gougis, C Moreau Bachelard, M Kamal, HK Gan, E Borcoman, ... JNCI Cancer Spectrum 3 (4), pkz055, 2019 | 48 | 2019 |
| Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward A Le Joncour, C Frere, I Martin-Toutain, P Gougis, P Ghillani-Dalbin, ... Autoimmunity Reviews 20 (2), 102729, 2021 | 34 | 2021 |
| Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial A Boilève, M Hilmi, P Gougis, R Cohen, B Rousseau, JF Blanc, ... European Journal of Cancer 143, 55-63, 2021 | 34 | 2021 |
| Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments P Gougis, M Hilmi, A Geraud, O Mir, C Funck-Brentano Critical Reviews in Oncology/Hematology 166, 103342, 2021 | 25 | 2021 |
| Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study JE Salem, M Bretagne, B Lebrun-Vignes, X Waintraub, E Gandjbakhch, ... Archives of cardiovascular diseases 112 (11), 699-712, 2019 | 24 | 2019 |
| Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis MYY Moey, P Gougis, V Goldschmidt, DB Johnson, B Lebrun-Vignes, ... European Respiratory Journal 55 (6), 2020 | 23 | 2020 |
| Optimizing drug development in oncology by clinical trial simulation: Why and how? J Gal, G Milano, JM Ferrero, E Saâda-Bouzid, J Viotti, S Chabaud, ... Briefings in bioinformatics 19 (6), 1203-1217, 2018 | 23 | 2018 |
| Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human … B Llopis, P Robidou, N Tissot, B Pinna, P Gougis, FC Aubart, L Campedel, ... Journal of Pharmaceutical and Biomedical Analysis 197, 113968, 2021 | 18 | 2021 |
| Clinical pharmacology of anti-angiogenic drugs in oncology P Gougis, J Wassermann, JP Spano, N Keynan, C Funck-Brentano, ... Critical Reviews in Oncology/Hematology 119, 75-93, 2017 | 17 | 2017 |
| Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? P Gougis, C Fenioux, C Funck-Brentano, M Veyri, J Gligorov, C Solas, ... European Journal of Cancer 136, 1-3, 2020 | 16 | 2020 |
| Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors B Abbar, V De Castelbajac, P Gougis, S Assoun, J Pluvy, C Tesmoingt, ... Lung Cancer 152, 109-118, 2021 | 14 | 2021 |
| Major pitfalls of protein kinase inhibitors prescription: a review of their clinical pharmacology for daily use P Gougis, LJ Palmieri, C Funck-Brentano, A Paci, R Flippot, O Mir, ... Critical Reviews in Oncology/Hematology 141, 112-124, 2019 | 14 | 2019 |
| Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis C Fenioux, B Abbar, S Boussouar, M Bretagne, JR Power, JJ Moslehi, ... Nature Medicine 29 (12), 3100-3110, 2023 | 11 | 2023 |
| Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma. AB El-Khoueiry, JP Spano, E Angevin, T Doi, AJ Bullock, WP Harris, ... Journal of Clinical Oncology 38 (4_suppl), 523-523, 2020 | 8 | 2020 |
